Australia based CSL Limited's part, CSL Behring has announced that the first patient has been enrolled in its ...
Melbourne-based Affinity Biosciences Pty Ltd (Affinity), a privately held company focused on antibody discovery for canc...
Australia’s commitment to support the health and wellbeing of the Pacific Island neighbours remains steadfast, wit...
The Australian Government is investing $19 million in transformative medical research projects using game-changing appli...
Alterity Therapeutics announced that it has received guidance from the US Food and Drug Administration (FDA) in relation...
US based Synchron Inc., a neurovascular bioelectronic medicine company, has announced that the University of Melbou...
The Mitra® microsampling device from US company Neoteryx has been registered as a Class I in vitro diagnostic (IVD) ...
The Australian government, together with the National Heart Foundation, is announcing a further $12 million for research...
The Australian Government is investing over $5.7 million to further develop traumatic brain injury research, aimed at im...
HONG KONG Prevalence CVD, including heart attack and stroke, is the third leading cause of death in Hong Kong (aft...
The Cost of Inaction: Secondary Prevention of Cardiovascular Disease in Asia-Pacific Rehabilitation ...
Clover Biopharmaceuticals, headquartered in China, has announced that the first participants have been dosed in the Phas...
Treatment effectiveness, health care costs and quality of life outcomes for the two to four percent of Australians with ...
Medical professionals will soon have access to a new device to treat the 3.24 million Australians who suffer chronic pai...
Australia based SpeeDx, a developer of innovative molecular diagnostic solutions, has partnered with Roche, a global pio...
The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital on 10 June 2020 that Australia current...
Australian firm Atomo Diagnostics Limited is pleased to announce it has expanded its existing COVID-19 rapid test p...
Novavax commenced Phase I clinical trial for their COVID-19 vaccine "NVX-CoV2373" a stable prefusion protein antige...
